Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024

Company Overview - Achieve Life Sciences, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of cytisinicline for smoking cessation and nicotine dependence [1][2] - The company will report its second quarter 2024 financial results and provide an update on the cytisinicline development program on August 13, 2024 [1] Industry Context - There are approximately 28 million adults in the United States who smoke combustible cigarettes, with tobacco use being the leading cause of preventable death, resulting in over 8 million deaths globally and nearly 500,000 deaths annually in the U.S. [2] - Smoking and exposure to secondhand smoke are responsible for more than 87% of lung cancer deaths, 61% of pulmonary disease deaths, and 32% of deaths from coronary heart disease [2] - Over 11 million adults in the U.S. use e-cigarettes, with 2.1 million middle and high school students reporting e-cigarette use in 2023 [2] Product Information - Cytisinicline is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors in the brain, aimed at treating nicotine addiction for both smoking and e-cigarette cessation [3] - The product is still investigational and has not received FDA approval for any indication in the United States [3]